Serrapeptase — Research Profile

SPU (Serratiopeptidase Units) measures the enzyme's proteolytic activity. A typical dose is 60,000-120,000 SPU (equivalent to 10-60mg). Some products use SU (Serrapeptase Units). Always compare enzymatic activity units, not just milligrams, when choosing products.

Serrapeptase is a protein enzyme that is destroyed by stomach acid. Enteric coating protects it until it reaches the alkaline environment of the small intestine, where it is absorbed intact into the bloodstream. Without enteric coating, most of the enzyme is inactivated before absorption.

Both are proteolytic enzymes used for inflammation. Serrapeptase has stronger fibrinolytic (clot-dissolving) activity, while bromelain has broader clinical evidence and COX-modulating effects. Some practitioners combine them. Bromelain has a larger evidence base, but serrapeptase may be superior for fibrin-related conditions.

An enteric-coated oral tablet or capsule is the standard and most defensible form, because uncoated serratiopeptidase is prone to enzymatic and acid degradation in the gastrointestinal tract before it can be absorbed. Non-enteric powders or chewables risk destroying much of the enzyme in the stomach. No head-to-head trial has shown one enteric brand or delivery system to be superior to another.

Benefits remain unproven by rigorous standards: the 2013 systematic review of 24 studies concluded that the existing scientific evidence is insufficient to support serratiopeptidase as an analgesic or health supplement, because the underlying trials were of poor methodology. It was studied across surgery, orthopedics, ENT, gynecology, and dentistry, but the strongest controlled signal is short-term reduction of ear-nose-throat inflammation symptoms in one placebo-controlled trial. Popular claims about dissolving arterial plaque, scar tissue, or chronic mucus are not backed by adequate human data.

No standardized dose has been established; the 2013 systematic review noted that dose and duration were often not even specified in the trials. Pharmaceutical formulation literature describes a commonly recommended oral regimen of 5-10 mg three times daily, and the ENT trial dosed two enteric-coated tablets three times daily. Because labeled enzyme units vary widely between products, follow the specific product's directions rather than a fixed milligram target.

Time of day has not been directly compared in trials; the controlled studies simply split the dose across three administrations per day. Enteric coating is what protects the enzyme from stomach acid, so its survival depends on the coating rather than a specific clock time. If a product directs taking it away from food, that instruction reflects manufacturer guidance rather than head-to-head evidence.

WebMD notes there is not enough research to characterize common side effects reliably. The reactions that are documented tend to be serious and uncommon: breathing problems or wheezing, swelling of the face, lips, or throat, and severe skin reactions including Stevens-Johnson syndrome and bullous pemphigoid. Beyond WebMD's list, a published case report documented serrapeptase-induced acute eosinophilic pneumonia that resolved after the enzyme was stopped, so any new breathing or skin symptoms warrant discontinuing it and seeking care.

WebMD identifies interactions with blood thinners (anticoagulants), antiplatelet drugs such as aspirin, clopidogrel, and ticagrelor, and NSAIDs like ibuprofen and naproxen, with the shared concern being increased bleeding risk. It also advises informing your provider before surgery. Because these interactions are not fully characterized, anyone on clot-affecting medication should clear serrapeptase with a clinician first.

There is no population for which serrapeptase is clearly evidence-supported; the 2013 systematic review found the data insufficient to recommend it as an analgesic or health supplement. Some people trial it as a short-term adjunct for ENT or post-inflammatory symptoms, but no group has strong controlled evidence of benefit. It should be avoided by anyone taking anticoagulant, antiplatelet, or NSAID medication, those facing surgery, and pregnant individuals, since safety in those groups is unestablished.

The best available onset data come from a single ENT trial in which enteric-coated serratia peptidase produced significant symptom regression after 3-4 days of dosing (two tablets three times daily), with further improvement by 7-8 days. That timeline reflects short-term inflammatory conditions and cannot be assumed for the joint, sinus, or cardiovascular uses often marketed. A 2013 systematic review cautioned that most serrapeptase trials were small and methodologically weak, so any expected timeframe is uncertain.

Long-term safety has not been established: the 2013 systematic review specifically noted that data on the safety, tolerability, and long-term use of serratiopeptidase are lacking. Existing trials ran only days to a few weeks, and rare but serious reactions have been reported, including severe skin reactions such as Stevens-Johnson syndrome and at least one published case report of serrapeptase-induced acute eosinophilic pneumonia after three months of use, which resolved once the enzyme was stopped. There is no evidence base to confirm that continuous daily use over months or years is safe.

No upper limit or toxicity threshold has been established for serrapeptase, and the 2013 systematic review found that even the intended dose and duration were often left unspecified in the trials. WebMD documents serious reactions linked to serrapeptase regardless of any formal overdose, including breathing problems, swelling of the face, lips, or throat, and severe skin reactions such as Stevens-Johnson syndrome and bullous pemphigoid. Taking more than a product directs is not supported by any evidence of added benefit or safety.

The main documented concern is bleeding: WebMD flags interactions with blood thinners and antiplatelet agents, so stacking serrapeptase with supplements that also affect clotting (fish oil, high-dose vitamin E, nattokinase, garlic) could compound that risk. It is frequently sold alongside bromelain or other proteolytic enzymes, but no controlled trials have tested those combinations for added benefit or safety. Anyone taking multiple blood-thinning supplements should get clinician oversight before adding it.

Enteric coating is the single most important feature: serratiopeptidase is a protein readily degraded by stomach acid, and enteric-coated tablets are formulated to hold the enzyme intact through simulated gastric fluid (pH 1.2) and release it in the intestine. Prioritize products that clearly specify enteric or acid-resistant delivery, and, because supplement enzymes are not tightly regulated, favor brands that offer third-party testing for potency and purity. Labeled potency conventions differ from product to product, so there is no single standardized unit that compares cleanly across brands.